• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evidence overview of therapeutic hypothermia]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evidence brief on the measures related to the reimbursement of blood glucose test strips]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Everolimus (Afinitor) for the treatment of renal cell carcinoma]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of vascular care in Alzheimer's disease]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the utility and indication of prostate biopsies with image fusion – magnetic resonance and transrectal ultrasound]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
1998     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of the use of antidigoxin antibodies in the treatment of digitalis intoxication]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of the potential of real-time 3-dimensional echocardiography in the assessment of right ventricular function in adult congenital heart disease: comparison of RT-3D echo with MRI]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the efficacy and safety of negative pressure in the treatment of chronic wounds]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the effectiveness of psychological intervention in the first psychotic episode by multidisciplinary treatment]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2009     Canary Health Service [Evaluation of the effectiveness and costs of Quantiferon-TB Gold for the diagnosis of latent tuberculosis infection in healthcare personnel]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Evaluation of the Danish National Cancer Action Plan - status and future monitoring - summary and proposals for focus areas]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the benefits and harms of statins (with particular consideration of atorvastatin)]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of technologies allowing the induction of therapeutic hypothermia in patients who have suffered a cardiac arrest]
2003     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of techniques for detecting breast implant rupture]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Evaluation of taking mifepristone at home during a medical abortion]
2011     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of subcutaneous-lead implantable cardioverter-defibrillators]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of regular searches in the ICTRP Search Portal]
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2023     Canary Health Service [Evaluation of patient involvement in health technology assessment]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of optical coherence tomography in the diagnosis of age related macular degeneration compared with fluorescence angiography]
2010     Haute Autorite de sante (HAS) [Evaluation of negative-pressure wound therapy]
2011     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Evaluation of multiple technologies for chronic wounds and burns]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity]
2014     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of l-caldesmon as biomarker for brain tumor monitoring]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Evaluation of implementation of foetal screening]
2024     Haute Autorite de sante (HAS) [Evaluation of high-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2016     Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of ethylene oxide sterilant alternatives: plasma and ozone]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficiency of organizational models for stroke management (stroke units)]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis targeting adolescents and young adults]